{"id":"https://openalex.org/W2005256857","doi":"https://doi.org/10.1007/s00192-013-2042-x","title":"A phase II dose-ranging study of mirabegron in patients with overactive bladder","display_name":"A phase II dose-ranging study of mirabegron in patients with overactive bladder","publication_year":2013,"publication_date":"2013-03-07","ids":{"openalex":"https://openalex.org/W2005256857","doi":"https://doi.org/10.1007/s00192-013-2042-x","mag":"2005256857","pmid":"https://pubmed.ncbi.nlm.nih.gov/23471546","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/3745617"},"language":"en","primary_location":{"id":"doi:10.1007/s00192-013-2042-x","doi":"https://doi.org/10.1007/s00192-013-2042-x","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s00192-013-2042-x","pdf_url":"https://link.springer.com/content/pdf/10.1007/s00192-013-2042-x.pdf","source":{"id":"https://openalex.org/S90591482","display_name":"International Urogynecology Journal","issn_l":"0937-3462","issn":["0937-3462","1433-3023"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International Urogynecology Journal","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://link.springer.com/content/pdf/10.1007/s00192-013-2042-x.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"On behalf of the Dragon Investigator Group","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210102902","display_name":"Sheffield Teaching Hospitals NHS Foundation Trust","ror":"https://ror.org/018hjpz25","country_code":"GB","type":"funder","lineage":["https://openalex.org/I4210102902"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"On behalf of the Dragon Investigator Group","raw_affiliation_strings":["Sheffield Teaching Hospitals"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sheffield Teaching Hospitals","institution_ids":["https://openalex.org/I4210102902"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080266362","display_name":"Christopher Reginald Chapple","orcid":"https://orcid.org/0000-0002-2960-9931","observed_orcids":["https://orcid.org/0000-0002-2960-9931"]},"institutions":[{"id":"https://openalex.org/I2801732343","display_name":"Royal Hallamshire Hospital","ror":"https://ror.org/00514rc81","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2801732343","https://openalex.org/I4210102902"]}],"countries":["GB"],"is_corresponding":true,"raw_author_name":"Christopher R. Chapple","raw_affiliation_strings":["Department of Urology, Royal Hallamshire Hospital, Sheffield Teaching Hospitals, Glossop Road, Sheffield, S10 2JF, UK. c.r.chapple@shef.ac.uk","Centrum ambulantn\u00ed gynekologie a prim\u00e1rn\u00ed p\u00e9ce"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Urology, Royal Hallamshire Hospital, Sheffield Teaching Hospitals, Glossop Road, Sheffield, S10 2JF, UK. c.r.chapple@shef.ac.uk","institution_ids":["https://openalex.org/I2801732343"]},{"raw_affiliation_string":"Centrum ambulantn\u00ed gynekologie a prim\u00e1rn\u00ed p\u00e9ce","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"Vladimir Dvorak","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I268303160","display_name":"Medical University of Warsaw","ror":"https://ror.org/04p2y4s44","country_code":"PL","type":"education","lineage":["https://openalex.org/I268303160"]}],"countries":["PL"],"is_corresponding":false,"raw_author_name":"Vladimir Dvorak","raw_affiliation_strings":["Centrum ambulantn\u00ed gynekologie a prim\u00e1rn\u00ed p\u00e9ce, Brno, Czech Republic","Medical University Warsaw"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Centrum ambulantn\u00ed gynekologie a prim\u00e1rn\u00ed p\u00e9ce, Brno, Czech Republic","institution_ids":[]},{"raw_affiliation_string":"Medical University Warsaw","institution_ids":["https://openalex.org/I268303160"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Pjotr Radziszewski","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I268303160","display_name":"Medical University of Warsaw","ror":"https://ror.org/04p2y4s44","country_code":"PL","type":"education","lineage":["https://openalex.org/I268303160"]},{"id":"https://openalex.org/I2800191616","display_name":"Maastricht University Medical Centre","ror":"https://ror.org/02d9ce178","country_code":"NL","type":"funder","lineage":["https://openalex.org/I2800191616"]}],"countries":["NL","PL"],"is_corresponding":false,"raw_author_name":"Pjotr Radziszewski","raw_affiliation_strings":["Department of Urology, Medical University Warsaw, Warsaw, Poland","Maastricht University Medical Center+"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Urology, Medical University Warsaw, Warsaw, Poland","institution_ids":["https://openalex.org/I268303160"]},{"raw_affiliation_string":"Maastricht University Medical Center+","institution_ids":["https://openalex.org/I2800191616"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002038596","display_name":"Philip Van Kerrebroeck","orcid":"https://orcid.org/0000-0002-4503-3864","observed_orcids":["https://orcid.org/0000-0002-4503-3864"]},"institutions":[{"id":"https://openalex.org/I2800191616","display_name":"Maastricht University Medical Centre","ror":"https://ror.org/02d9ce178","country_code":"NL","type":"funder","lineage":["https://openalex.org/I2800191616"]},{"id":"https://openalex.org/I4210102047","display_name":"Antwerp University Hospital","ror":"https://ror.org/01hwamj44","country_code":"BE","type":"funder","lineage":["https://openalex.org/I4210102047"]}],"countries":["BE","NL"],"is_corresponding":false,"raw_author_name":"Philip Van Kerrebroeck","raw_affiliation_strings":["Department Urology, Maastricht University Medical Center, Maastricht, The Netherlands","Antwerp University and Antwerp University Hospital"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department Urology, Maastricht University Medical Center, Maastricht, The Netherlands","institution_ids":["https://openalex.org/I2800191616"]},{"raw_affiliation_string":"Antwerp University and Antwerp University Hospital","institution_ids":["https://openalex.org/I4210102047"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043271778","display_name":"Jean\u2010Jacques Wyndaele","orcid":"https://orcid.org/0000-0002-0879-6854","observed_orcids":["https://orcid.org/0000-0002-0879-6854"]},"institutions":[{"id":"https://openalex.org/I4210102047","display_name":"Antwerp University Hospital","ror":"https://ror.org/01hwamj44","country_code":"BE","type":"funder","lineage":["https://openalex.org/I4210102047"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"Jean Jacques Wyndaele","raw_affiliation_strings":["Department of Urology, Antwerp University and Antwerp University Hospital, Antwerp, Belgium","Astellas Pharma Europe BV"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Urology, Antwerp University and Antwerp University Hospital, Antwerp, Belgium","institution_ids":["https://openalex.org/I4210102047"]},{"raw_affiliation_string":"Astellas Pharma Europe BV","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086289312","display_name":"Brigitte Bosman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210157866","display_name":"Astellas Pharma (Netherlands)","ror":"https://ror.org/04kyfd050","country_code":"NL","type":"company","lineage":["https://openalex.org/I142395110","https://openalex.org/I4210157866"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Brigitte Bosman","raw_affiliation_strings":["Astellas Pharma Europe BV, Leiden, The Netherlands","Astellas Pharma Europe BV"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Astellas Pharma Europe BV, Leiden, The Netherlands","institution_ids":["https://openalex.org/I4210157866"]},{"raw_affiliation_string":"Astellas Pharma Europe BV","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005924474","display_name":"Peter J. Boerrigter","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210157866","display_name":"Astellas Pharma (Netherlands)","ror":"https://ror.org/04kyfd050","country_code":"NL","type":"company","lineage":["https://openalex.org/I142395110","https://openalex.org/I4210157866"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Peter Boerrigter","raw_affiliation_strings":["Astellas Pharma Europe BV, Leiden, The Netherlands","Astellas Pharma Europe BV"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Astellas Pharma Europe BV, Leiden, The Netherlands","institution_ids":["https://openalex.org/I4210157866"]},{"raw_affiliation_string":"Astellas Pharma Europe BV","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081498366","display_name":"Ted Drogendijk","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210157866","display_name":"Astellas Pharma (Netherlands)","ror":"https://ror.org/04kyfd050","country_code":"NL","type":"company","lineage":["https://openalex.org/I142395110","https://openalex.org/I4210157866"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Ted Drogendijk","raw_affiliation_strings":["Astellas Pharma Europe BV, Leiden, The Netherlands","Astellas Pharma Europe BV"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Astellas Pharma Europe BV, Leiden, The Netherlands","institution_ids":["https://openalex.org/I4210157866"]},{"raw_affiliation_string":"Astellas Pharma Europe BV","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065452127","display_name":"Arwin M. Ridder","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210157866","display_name":"Astellas Pharma (Netherlands)","ror":"https://ror.org/04kyfd050","country_code":"NL","type":"company","lineage":["https://openalex.org/I142395110","https://openalex.org/I4210157866"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Arwin Ridder","raw_affiliation_strings":["Astellas Pharma Europe BV, Leiden, The Netherlands","Astellas Pharma Europe BV"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Astellas Pharma Europe BV, Leiden, The Netherlands","institution_ids":["https://openalex.org/I4210157866"]},{"raw_affiliation_string":"Astellas Pharma Europe BV","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087773395","display_name":"Ingrid van der Putten-Slob","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I104946051","display_name":"Nihon University","ror":"https://ror.org/05jk51a88","country_code":"JP","type":"education","lineage":["https://openalex.org/I104946051"]},{"id":"https://openalex.org/I4210157866","display_name":"Astellas Pharma (Netherlands)","ror":"https://ror.org/04kyfd050","country_code":"NL","type":"company","lineage":["https://openalex.org/I142395110","https://openalex.org/I4210157866"]}],"countries":["JP","NL"],"is_corresponding":false,"raw_author_name":"Ingrid Van Der Putten-Slob","raw_affiliation_strings":["Astellas Pharma Europe BV, Leiden, The Netherlands","Nihon University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Astellas Pharma Europe BV, Leiden, The Netherlands","institution_ids":["https://openalex.org/I4210157866"]},{"raw_affiliation_string":"Nihon University","institution_ids":["https://openalex.org/I104946051"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5033408219","display_name":"Osamu Yamaguchi","orcid":"https://orcid.org/0000-0002-7461-369X","observed_orcids":["https://orcid.org/0000-0002-7461-369X"]},"institutions":[{"id":"https://openalex.org/I104946051","display_name":"Nihon University","ror":"https://ror.org/05jk51a88","country_code":"JP","type":"education","lineage":["https://openalex.org/I104946051"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Osamu Yamaguchi","raw_affiliation_strings":["Division of Bioengineering and LUTD Research, School of Engineering, Nihon University, Koriyama, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Bioengineering and LUTD Research, School of Engineering, Nihon University, Koriyama, Japan","institution_ids":["https://openalex.org/I104946051"]}]}],"institutions":[],"countries_distinct_count":5,"institutions_distinct_count":7,"corresponding_author_ids":["https://openalex.org/A5080266362"],"corresponding_institution_ids":["https://openalex.org/I2801732343"],"apc_list":{"value":3790,"currency":"USD","value_usd":3790},"apc_paid":{"value":3790,"currency":"USD","value_usd":3790},"fwci":21.4951,"has_fulltext":true,"cited_by_count":137,"citation_normalized_percentile":{"value":0.99673108,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":94,"max":100},"biblio":{"volume":"24","issue":"9","first_page":"1447","last_page":"1458"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10279","display_name":"Urinary Bladder and Prostate Research","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2748","display_name":"Urology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10279","display_name":"Urinary Bladder and Prostate Research","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2748","display_name":"Urology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10418","display_name":"Pelvic floor disorders treatments","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11232","display_name":"Urinary Tract Infections Management","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/mirabegron","display_name":"mirabegron","score":1.0},{"id":"https://openalex.org/keywords/overactive-bladder","display_name":"overactive bladder","score":0.9990000128746033},{"id":"https://openalex.org/keywords/beta3-adrenergic-agonists","display_name":"beta3-adrenergic agonists","score":0.9200000166893005},{"id":"https://openalex.org/keywords/dose-ranging-study","display_name":"dose-ranging","score":0.7870000004768372},{"id":"https://openalex.org/keywords/tolterodine-extended-release","display_name":"tolterodine extended release","score":0.8579999804496765},{"id":"https://openalex.org/keywords/micturition-frequency","display_name":"micturition frequency","score":0.9309999942779541},{"id":"https://openalex.org/keywords/urinary-urgency","display_name":"urinary urgency","score":0.781000018119812},{"id":"https://openalex.org/keywords/urinary-incontinence","display_name":"urinary incontinence","score":0.9120000004768372},{"id":"https://openalex.org/keywords/nocturia","display_name":"nocturia","score":0.9909999966621399},{"id":"https://openalex.org/keywords/quality-of-life","display_name":"quality of life","score":0.8830000162124634},{"id":"https://openalex.org/keywords/pulse-rate","display_name":"pulse rate","score":0.7379999756813049},{"id":"https://openalex.org/keywords/cardiovascular-safety","display_name":"cardiovascular safety","score":0.6129999756813049},{"id":"https://openalex.org/keywords/post-void-residual-urine","display_name":"post-void residual urine","score":0.8579999804496765}],"concepts":[{"id":"https://openalex.org/C2778164427","wikidata":"https://www.wikidata.org/wiki/Q3702534","display_name":"Mirabegron","level":4,"score":0.9401788711547852},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8986115455627441},{"id":"https://openalex.org/C2778941218","wikidata":"https://www.wikidata.org/wiki/Q331231","display_name":"Overactive bladder","level":3,"score":0.8958248496055603},{"id":"https://openalex.org/C175768497","wikidata":"https://www.wikidata.org/wiki/Q105726","display_name":"Urination","level":3,"score":0.7728515863418579},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.7670509219169617},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.7406325936317444},{"id":"https://openalex.org/C2777333188","wikidata":"https://www.wikidata.org/wiki/Q1426443","display_name":"Nocturia","level":3,"score":0.6956312656402588},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.6935179233551025},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5926614999771118},{"id":"https://openalex.org/C2776312127","wikidata":"https://www.wikidata.org/wiki/Q5299247","display_name":"Dose-ranging study","level":5,"score":0.5580978989601135},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.5137032270431519},{"id":"https://openalex.org/C2778531004","wikidata":"https://www.wikidata.org/wiki/Q281490","display_name":"Urinary incontinence","level":2,"score":0.46311062574386597},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.3498098850250244},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.34374868869781494},{"id":"https://openalex.org/C77411442","wikidata":"https://www.wikidata.org/wiki/Q181100","display_name":"Urinary system","level":2,"score":0.31838458776474},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C2991744798","wikidata":"https://www.wikidata.org/wiki/Q608510","display_name":"Double blind","level":4,"score":0.0}],"mesh":[{"descriptor_ui":"D000083","descriptor_name":"Acetanilides","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000083","descriptor_name":"Acetanilides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011788","descriptor_name":"Quality of Life","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013844","descriptor_name":"Thiazoles","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D013844","descriptor_name":"Thiazoles","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D014549","descriptor_name":"Urinary Incontinence","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D015994","descriptor_name":"Incidence","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016037","descriptor_name":"Single-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D038622","descriptor_name":"Internationality","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D053201","descriptor_name":"Urinary Bladder, Overactive","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D058667","descriptor_name":"Adrenergic beta-3 Receptor Agonists","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D058667","descriptor_name":"Adrenergic beta-3 Receptor Agonists","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":8,"locations":[{"id":"doi:10.1007/s00192-013-2042-x","doi":"https://doi.org/10.1007/s00192-013-2042-x","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s00192-013-2042-x","pdf_url":"https://link.springer.com/content/pdf/10.1007/s00192-013-2042-x.pdf","source":{"id":"https://openalex.org/S90591482","display_name":"International Urogynecology Journal","issn_l":"0937-3462","issn":["0937-3462","1433-3023"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International Urogynecology Journal","raw_type":"journal-article"},{"id":"pmh:oai:europepmc.org:2738935","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/3745617","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":null,"raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:3745617","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/3745617","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Int Urogynecol J","raw_type":"Text"},{"id":"pmid:23471546","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/23471546","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International urogynecology journal","raw_type":"Clinical Trial, Phase II"},{"id":"pmh:oai:cris.maastrichtuniversity.nl:openaire/8c781c1e-378d-4d98-a6ae-52bb68124f3d","doi":null,"is_oa":true,"landing_page_url":"https://cris.maastrichtuniversity.nl/en/publications/8c781c1e-378d-4d98-a6ae-52bb68124f3d","pdf_url":null,"source":{"id":"https://openalex.org/S4306402616","display_name":"Research Publications (Maastricht University)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I34352273","host_organization_name":"Maastricht University","host_organization_lineage":["https://openalex.org/I34352273"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Chapple, C R, Dvorak, V, Radziszewski, P, Van Kerrebroeck, P, Wyndaele, J J, Bosman, B, Boerrigter, P, Drogendijk, T, Ridder, A, Van der Putten-Slob, I & Yamaguchi, O 2013, 'A phase II dose-ranging study of mirabegron in patients with overactive bladder', International Urogynecology Journal, vol. 24, no. 9, pp. 1447-1458. https://doi.org/10.1007/s00192-013-2042-x","raw_type":"info:eu-repo/semantics/article"},{"id":"pmh:oai:eprints.whiterose.ac.uk:115353","doi":null,"is_oa":false,"landing_page_url":"http://eprints.whiterose.ac.uk/115353/1/A%20phase%20II%20dose-ranging%20study%20of%20mirabegron%20in%20patients%20with%20overactive%20bladder.pdf","pdf_url":"http://eprints.whiterose.ac.uk/115353/1/A%20phase%20II%20dose-ranging%20study%20of%20mirabegron%20in%20patients%20with%20overactive%20bladder.pdf","source":{"id":"https://openalex.org/S4306400854","display_name":"White Rose Research Online (University of Leeds, The University of Sheffield, University of York)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I2800616092","host_organization_name":"White Rose University Consortium","host_organization_lineage":["https://openalex.org/I2800616092"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"","raw_type":"Article"},{"id":"pmh:oai:iris.uniroma1.it:11573/594387","doi":null,"is_oa":false,"landing_page_url":"http://hdl.handle.net/11573/594387","pdf_url":null,"source":{"id":"https://openalex.org/S4377196107","display_name":"IRIS Research product catalog (Sapienza University of Rome)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"info:eu-repo/semantics/article"},{"id":"pmh:um:oai:cris.maastrichtuniversity.nl:publications/8c781c1e-378d-4d98-a6ae-52bb68124f3d","doi":null,"is_oa":true,"landing_page_url":"https://cris.maastrichtuniversity.nl/en/publications/8c781c1e-378d-4d98-a6ae-52bb68124f3d","pdf_url":null,"source":{"id":"https://openalex.org/S4306402616","display_name":"Research Publications (Maastricht University)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I34352273","host_organization_name":"Maastricht University","host_organization_lineage":["https://openalex.org/I34352273"],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"International Urogynecology Journal, 24(9), 1447 - 1458. Springer-Verlag London Ltd.","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":{"id":"doi:10.1007/s00192-013-2042-x","doi":"https://doi.org/10.1007/s00192-013-2042-x","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s00192-013-2042-x","pdf_url":"https://link.springer.com/content/pdf/10.1007/s00192-013-2042-x.pdf","source":{"id":"https://openalex.org/S90591482","display_name":"International Urogynecology Journal","issn_l":"0937-3462","issn":["0937-3462","1433-3023"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International Urogynecology Journal","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/randomized-controlled-trial","display_name":"Randomized Controlled Trial"},{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320307758","display_name":"Eli Lilly and Company","ror":"https://ror.org/01qat3289"},{"id":"https://openalex.org/F4320307765","display_name":"Pfizer","ror":"https://ror.org/01xdqrp08"},{"id":"https://openalex.org/F4320316495","display_name":"Kissei","ror":"https://ror.org/028gkfr23"},{"id":"https://openalex.org/F4320323024","display_name":"Astellas Pharma","ror":"https://ror.org/01cjash87"},{"id":"https://openalex.org/F4320323599","display_name":"Astellas Pharma Europe","ror":"https://ror.org/018788w33"},{"id":"https://openalex.org/F4320328455","display_name":"Ipsen","ror":"https://ror.org/00d801g55"},{"id":"https://openalex.org/F4320332585","display_name":"Allergan","ror":"https://ror.org/00wthd003"},{"id":"https://openalex.org/F4320335039","display_name":"Narodowe Centrum Bada\u0144 i Rozwoju","ror":"https://ror.org/05pwfyy15"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2005256857.pdf","grobid_xml":"https://content.openalex.org/works/W2005256857.grobid-xml"},"referenced_works_count":24,"referenced_works":["https://openalex.org/W1507591711","https://openalex.org/W1583587392","https://openalex.org/W1590256680","https://openalex.org/W1928285801","https://openalex.org/W1967312126","https://openalex.org/W1968860914","https://openalex.org/W1972477468","https://openalex.org/W1980809057","https://openalex.org/W2032126389","https://openalex.org/W2033285271","https://openalex.org/W2046564720","https://openalex.org/W2083580221","https://openalex.org/W2091330746","https://openalex.org/W2102524054","https://openalex.org/W2104967317","https://openalex.org/W2105391780","https://openalex.org/W2109504141","https://openalex.org/W2131770336","https://openalex.org/W2133603145","https://openalex.org/W2161533975","https://openalex.org/W2161911161","https://openalex.org/W2275176429","https://openalex.org/W4244865769","https://openalex.org/W4406065656"],"related_works":["https://openalex.org/W1738560352","https://openalex.org/W1605716039","https://openalex.org/W2067945145","https://openalex.org/W1787320721","https://openalex.org/W1579782291","https://openalex.org/W2227211270","https://openalex.org/W1857858802","https://openalex.org/W2095517557","https://openalex.org/W2082897746","https://openalex.org/W2156905627"],"abstract_inverted_index":{"INTRODUCTION":[0],"AND":[1],"HYPOTHESIS:":[2],"Mirabegron":[3,134],"is":[4],"a":[5,30,181,202,253],"potent":[6],"and":[7,105,113,129,138,157,176,217,236],"selective":[8],"\u03b23-adrenoceptor":[9],"agonist":[10],"that":[11],"may":[12],"represent":[13],"an":[14,225],"alternative":[15],"treatment":[16,46],"option":[17],"in":[18,80,91,142,150,210,213,240],"place":[19],"of":[20,40,83,99,110,115,153,196,228,238],"antimuscarinics":[21],"for":[22,171,190],"patients":[23],"with":[24,47,166,185,188,224],"overactive":[25],"bladder.":[26],"METHODS:":[27],"Patients":[28],"completed":[29],"single-blinded,":[31],"2-week":[32],"placebo":[33,62,167,189],"run-in":[34],"period":[35],"followed":[36],"by":[37],"12":[38],"weeks":[39],"randomized":[41],"(n":[42],"=":[43],"928)":[44],"double-blinded":[45],"mirabegron":[48,173,186,215,239],"oral":[49],"controlled":[50],"absorption":[51],"system":[52],"(OCAS)":[53],"25,":[54,135],"50,":[55,136],"100,":[56,137],"or":[57,63],"200":[58,139],"mg":[59,69,140],"once-daily":[60],"(QD),":[61],"tolterodine":[64],"extended":[65],"release":[66],"(ER)":[67],"4":[68],"QD.":[70],"The":[71,233],"primary":[72],"endpoint":[73],"was":[74,180,201,221],"change":[75],"from":[76,146,208],"baseline":[77,147,209],"to":[78,148,248],"end-of-treatment":[79,149],"mean":[81,92,97],"number":[82,98],"micturition":[84,151],"episodes/24":[85,107],"h.":[86],"Secondary":[87],"endpoints":[88,193],"included":[89,120],"changes":[90],"volume":[93],"voided":[94],"per":[95],"micturition;":[96],"urinary":[100,103],"incontinence,":[101,104],"urgency":[102,106],"h;":[108],"severity":[109],"urgency;":[111],"nocturia;":[112],"quality":[114,195],"life":[116,197],"measures.":[117],"Safety":[118],"parameters":[119],"vital":[121],"signs,":[122],"adverse":[123,230],"events,":[124],"laboratory":[125],"tests,":[126],"electrocardiogram":[127],"measurements":[128],"post-void":[130],"residual":[131],"volume.":[132],"RESULTS:":[133],"resulted":[141],"dose-dependent":[143],"reductions":[144],"(improvements)":[145],"frequency":[152],"1.9,":[154],"2.1,":[155,156],"2.2":[158],"micturitions/24":[159,164],"h":[160,165],"respectively,":[161],"versus":[162],"1.4":[163],"(p":[168,204],"\u2264":[169],"0.05":[170],"the":[172,214],"50-,":[174],"100-,":[175],"200-mg":[177,218],"comparisons).":[178],"There":[179],"statistically":[182],"significant":[183,203],"improvement":[184],"compared":[187],"most":[191],"secondary":[192],"including":[194],"variables.":[198],"While":[199],"there":[200],"<":[205],"0.05)":[206],"increase":[207],"pulse":[211],"rate":[212],"100-mg":[216],"groups,":[219],"this":[220,241],"not":[222],"associated":[223],"increased":[226],"incidence":[227],"cardiovascular":[229],"events.":[231],"CONCLUSIONS:":[232],"favorable":[234],"efficacy":[235],"tolerability":[237],"phase":[242,254],"II":[243],"dose-finding":[244],"study":[245],"has":[246],"led":[247],"its":[249],"successful":[250],"advancement":[251],"into":[252],"III":[255],"clinical":[256],"development":[257],"program.":[258]},"counts_by_year":[{"year":2026,"cited_by_count":4},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":5},{"year":2023,"cited_by_count":11},{"year":2022,"cited_by_count":6},{"year":2021,"cited_by_count":9},{"year":2020,"cited_by_count":8},{"year":2019,"cited_by_count":8},{"year":2018,"cited_by_count":17},{"year":2017,"cited_by_count":14},{"year":2016,"cited_by_count":16},{"year":2015,"cited_by_count":14},{"year":2014,"cited_by_count":14},{"year":2013,"cited_by_count":9}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}